Market Place
Sourcing Support
Anavex Reports Preliminary Biomarker Results For ANAVEX®3-71
17 Oct 2024 //
GLOBENEWSWIRE
Anavex Life Sciences to Present at H.C. Wainwright Global Conference 2024
03 Sep 2024 //
GLOBENEWSWIRE
Anavex Life Sciences Reports Q3 2024 Results And Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Anavex To Announce Q3 2024 Results On August 6
01 Aug 2024 //
GLOBENEWSWIRE
Anavex Presents ANAVEX®2-73 Biomarker Data In Fragile X Syndrome
30 Jul 2024 //
GLOBENEWSWIRE
Anavex Presents Blarcamesine Phase IIb/III Trial Results At AAIC
28 Jul 2024 //
GLOBENEWSWIRE
Anavex To Present At H.C. Wainwright 5th Annual Neuro Perspectives Conference
20 Jun 2024 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Expansion of Leadership Team
22 May 2024 //
GLOBENEWSWIRE
Anavex To Present At H.C. Wainwright BioConnect NASDAQ Conference
14 May 2024 //
GLOBENEWSWIRE
Anavex Life Sciences Q2 FY2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Anavex Q2 FY2024 Results On May 9
02 May 2024 //
GLOBENEWSWIRE
Anavex At Noble Virtual Healthcare Equity Conference
11 Apr 2024 //
GLOBENEWSWIRE
Anavex Initiates Phase 2 Clinical Trial of ANAVEX®3-71
18 Mar 2024 //
GLOBENEWSWIRE
Anavex Life to Present at the 44th Annual TD Cowen Health Care Conference
26 Feb 2024 //
GLOBENEWSWIRE
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results
07 Feb 2024 //
GLOBENEWSWIRE
Anavex Life Announces U.S. Phase 2 Trial of ANAVEX®3-71 in Schizophrenia
16 Jan 2024 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine
08 Jan 2024 //
GLOBENEWSWIRE
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Anavex’s experimental drug fails Rett syndrome study, stock falls
03 Jan 2024 //
ENDPTS
Anavex Announces First Gene Pathway Data of ANAVEX 2-73 from AVATAR Study
20 Dec 2023 //
GLOBENEWSWIRE
Anavex Received Agreement from CHMP for Submission of a MAA of Oral Blarcamesine
19 Dec 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results
27 Nov 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine
22 Nov 2023 //
GLOBENEWSWIRE
Anavex Initiates Regulatory Submission of Blarcamesine for Alzheimers Disease
20 Nov 2023 //
GLOBENEWSWIRE
Anavex Life Reports Publication Demonstrating the Potential of ANAVEX®3-71
25 Oct 2023 //
GLOBENEWSWIRE
Anavex`s Phase 2b/3 Trial of Blarcamesine Shows Robust Clinical Efficacy
14 Sep 2023 //
GLOBENEWSWIRE
Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman
12 Sep 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
08 Aug 2023 //
FINANCE YAHOO
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal
07 Aug 2023 //
GLOBENEWSWIRE
Anavex Life to Present at the BTIG Virtual Biotechnology Conference 2023
02 Aug 2023 //
GLOBENEWSWIRE
Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results
01 Aug 2023 //
GLOBENEWSWIRE
Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73
28 Jun 2023 //
GLOBENEWSWIRE
Anavex & Partex announce AI-based partnership to enhance patient experience
28 Jun 2023 //
PHARMAFILE
ANAVEX®2-73 Receives Compassionate Use for Pediatric Patients
15 Jun 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Completion of ANAVEX EXCELLENCE Phase 2/3 Trial
06 Jun 2023 //
GLOBENEWSWIRE
ANAVEX Announces Issuance of Property Compositions Patent for ANAVEX2-73
01 Jun 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
09 May 2023 //
GLOBENEWSWIRE
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter FYR on Tuesday
02 May 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX
01 May 2023 //
GLOBENEWSWIRE
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Conference
25 Apr 2023 //
GLOBENEWSWIRE
Anavex to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
10 Apr 2023 //
GLOBENEWSWIRE
Anavex Life Appoints Former FDA Lead Neurology Statistician as VP Head
09 Mar 2023 //
GLOBENEWSWIRE
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
07 Feb 2023 //
GLOBENEWSWIRE
Anavex Announces Exceeding of Enrollment Target for the ANAVEX 2-73 EXCELLENCE Phase 2/3 Trial
02 Feb 2023 //
GLOBENEWSWIRE
Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results
31 Jan 2023 //
GLOBENEWSWIRE
Anavex Strengthens Advisory Board from Ph 2b/3 Alzheimer’s Trial
14 Dec 2022 //
GLOBENEWSWIRE
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare
12 Dec 2022 //
GLOBENEWSWIRE
Is Anavex Life Sciences a Smart Stock to Buy Now?
03 Dec 2022 //
FOOL
Anavex Life Sciences to Announce Management Webcast and Conference Call
02 Dec 2022 //
GLOBENEWSWIRE
Anavex (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints
01 Dec 2022 //
GLOBENEWSWIRE
Anavex Reports Fiscal 2022 Year End Financial Results & Provides Business Update
28 Nov 2022 //
GLOBENEWSWIRE
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial ResultsÂ
23 Nov 2022 //
GLOBENEWSWIRE
Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology
08 Nov 2022 //
GLOBENEWSWIRE
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX®2-73
07 Nov 2022 //
GLOBENEWSWIRE
Anavex Life Announces Late-Breaking Presentation of P 2b/3 Data of Oral ANAVEX®
17 Oct 2022 //
GLOBENEWSWIRE
Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73
21 Sep 2022 //
GLOBENEWSWIRE
Anavex Publishes in Medical Journal on Relevance of SIGMAR1 Activation
23 Aug 2022 //
GLOBENEWSWIRE
Anavex Life Sciences Reports Fiscal 2022 Third Quarter Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
